Literature DB >> 12580963

Expansion of CD8+ T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma.

Ourania Katopodis1, Stamatis-Nick Liossis, Vassilios Viglis, Anastasia Pouli, Meletios-Athanasios Dimopoulos, Petros P Sfikakis.   

Abstract

An expanded cytotoxic/memory T-cell subpopulation expressing low levels of the B-cell-specific CD20 molecule was found in peripheral blood and bone marrow of patients with multiple myeloma at the time of diagnosis, but returned to normal levels following treatment. CD3+CD20dim cells were also increased in monoclonal gammopathy of unknown significance albeit at lower levels. Lower CD3+CD20dim cell numbers at baseline may be associated with lack of response to treatment and a poor outcome. Because expansion of these T cells may be related to disease status, further studies should investigate their potentially unique function in plasma cell dyscrasias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12580963     DOI: 10.1046/j.1365-2141.2003.04087.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA.

Authors:  Genevieve E Martin; Matthew Pace; John P Thornhill; Chansavath Phetsouphanh; Jodi Meyerowitz; Morgane Gossez; Helen Brown; Natalia Olejniczak; Julianne Lwanga; Gita Ramjee; Pontiano Kaleebu; Kholoud Porter; Christian B Willberg; Paul Klenerman; Nneka Nwokolo; Julie Fox; Sarah Fidler; John Frater
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

2.  CD32+CD4+ T Cells Sharing B Cell Properties Increase With Simian Immunodeficiency Virus Replication in Lymphoid Tissues.

Authors:  Nicolas Huot; Philippe Rascle; Cyril Planchais; Vanessa Contreras; Caroline Passaes; Roger Le Grand; Anne-Sophie Beignon; Etienne Kornobis; Rachel Legendre; Hugo Varet; Asier Saez-Cirion; Hugo Mouquet; Beatrice Jacquelin; Michaela Müller-Trutwin
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.